文献速递白血病贫血与红细胞疾病

急性髓系白血病IDH1/2突变与冠心病及心功能不全风险的回顾性倾向评分分析

IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis.
PubMed 文献 · Leukemia · 2020-09-18

该回顾性观察研究纳入363例急性髓系白血病(AML)患者,检出IDH1突变26例(7.2%)、IDH2突变39例(10.7%)。IDH1突变者冠心病患病率显著更高(26.1% vs. 6.4%,p=0.002);经逆概率加权分析,IDH1/2突变者在AML治疗期间心功能下降风险高于野生型。机制上R-2HG加重多柔比星心脏毒性。

要点

  • IDH1突变AML患者冠心病患病率26.1%,显著高于无突变者6.4%(p=0.002)。
  • IDH1/2突变者治疗期间左室射血分数由59.2%降至41.9%(p<0.001),野生型无显著变化。
  • 评估IDH1/2突变状态或有助于识别细胞毒治疗期间心血管并发症高危的AML患者。

核心结论

  • AML患者中IDH1/2突变可能与冠心病患病率升高及治疗期间心功能下降风险增加相关。
  • 评估IDH1/2突变状态可能有助于识别细胞毒治疗期间心血管并发症高危的AML患者。

研究设计与样本

  • 回顾性观察性研究,纳入363例急性髓系白血病患者。
  • 采用逆概率加权分析比较IDH1/2突变型与野生型患者的心功能变化。

主要发现

  • 363例中IDH1突变26例(7.2%),IDH2突变39例(10.7%)。
  • IDH1突变患者冠心病患病率26.1%,高于非突变者的6.4%(p=0.002)。
  • IDH1/2突变者左室射血分数从治疗前59.2%降至诊断后10个月的41.9%(p<0.001);野生型从58.5%降至55.4%(p=0.27)。
  • hiPS来源心肌细胞的RNA测序与免疫染色提示,肿瘤代谢物R-2HG加重多柔比星介导的心脏毒性。

关键数值与推荐

  • IDH1突变患病率7.2%(26/363),IDH2突变患病率10.7%(39/363)。
  • 冠心病患病率比较:26.1% vs. 6.4%,p=0.002。
  • 左室射血分数:突变型59.2%→41.9%(p<0.001),野生型58.5%→55.4%(p=0.27)。

临床怎么用

  • 对AML患者可考虑评估IDH1/2突变状态,以辅助识别细胞毒治疗期间心血管并发症高危人群。
  • IDH1/2突变患者在接受含多柔比星等细胞毒治疗时宜关注心功能监测。

局限性

  • 为回顾性观察性研究,样本量363例,结果需前瞻性研究验证。
  • 机制证据主要来自hiPS来源心肌细胞的RNA测序与免疫染色,尚需进一步体内验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clonal hematopoiesis of indeterminate potential (CHIP) is linked to leukemia gene mutations and associates with an increased risk for coronary artery disease and poor prognosis in ischemic cardiomyopathy. Two recurrently mutated genes in CHIP and adult acute myeloid leukemia (AML) encode for isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2). Global expression of mutant IDH2 in transgenic mice-induced dilated cardiomyopathy and muscular dystrophy. In this retrospective observational study, we investigated whether mutant IDH1/2 predisposes to cardiovascular disease in AML patients. Among 363 AML patients, IDH1 and IDH2 mutations were detected in 26 (7.2%) and 39 patients (10.7%), respectively. Mutant IDH1 patients exhibited a significantly higher prevalence of coronary artery disease (26.1% vs. 6.4%, p = 0.002). Applying inverse probability-weighting analysis, patients with IDH1/2 mutations had a higher risk for a declining cardiac function during AML treatment compared to IDH1/2 wild type patients [left ventricular ejection fraction pretreatment compared to 10 months after diagnosis: 59.2% to 41.9% (p < 0.001) vs 58.5% to 55.4% (p = 0.27), respectively]. Mechanistically, RNA sequencing and immunostaining in hiPS-derived cardiomyocytes indicated that the oncometabolite R-2HG exacerbated doxorubicin mediated cardiotoxicity. Evaluation of IDH1/2 mutation status may therefore help identifying AML patients at risk for cardiovascular complications during cytotoxic treatment.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kattih B, Shirvani A, Klement P, et al. IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis. Leukemia. 2020. PMID: 32948843. doi:10.1038/s41375-020-01043-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。